Ocaratuzumab
- CAS No.
- 1169956-08-4
- Chemical Name:
- Ocaratuzumab
- Synonyms
- Ocaratuzumab;Ocaratuzumab (anti-CD20);Research Grade Ocaratuzumab
- CBNumber:
- CB08080862
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Ocaratuzumab 95.00% | CS-0621098 | 1mg | $379 |
| Ocaratuzumab 95.00% | CS-0621098 | 5mg | $986 |
| Ocaratuzumab 95.00% | CS-0621098 | 10mg | $1571 |
| Ocaratuzumab ≥95%(SDS-PAGE&SEC-HPLC) | AA0294S4 | 1mg | $580 |
| Ocaratuzumab ≥95%(SDS-PAGE&SEC-HPLC) | AA0294S4 | 5mg | $1558 |
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | NTY9893GD0 |
| NCI Drug Dictionary | ocaratuzumab |
Ocaratuzumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0621098 | Ocaratuzumab 95.00% | 1169956-08-4 | 1mg | $379 | 2026-06-04 | Buy |
| ChemScene | CS-0621098 | Ocaratuzumab 95.00% | 1169956-08-4 | 5mg | $986 | 2026-06-04 | Buy |
| ChemScene | CS-0621098 | Ocaratuzumab 95.00% | 1169956-08-4 | 10mg | $1571 | 2026-06-04 | Buy |
| aablocks | AA0294S4 | Ocaratuzumab ≥95%(SDS-PAGE&SEC-HPLC) | 1169956-08-4 | 1mg | $580 | 2026-06-02 | Buy |
| aablocks | AA0294S4 | Ocaratuzumab ≥95%(SDS-PAGE&SEC-HPLC) | 1169956-08-4 | 5mg | $1558 | 2026-06-02 | Buy |
Ocaratuzumab Chemical Properties,Uses,Production
Uses
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC)[1][2].
References
[1] Forero-Torres A, et, al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18(5):1395-403. DOI:10.1158/1078-0432.CCR-11-0850
[2] Cheney CM, et, al. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs. 2014 May-Jun;6(3):749-55. DOI:10.4161/mabs.28282
Ocaratuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
Ocaratuzumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 021-61312847; 18021002903 | 3008007409@qq.com | China | 89686 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1566 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10308 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9865 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7083 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11972 | 58 |
| Shanghai Aladdin Biochemical Technology Co.,Ltd. | 6206333 13167063860 | anhua.mao@aladdin-e.com | China | 49997 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 15111215862 18229892877 | 3062105966@qq.com | China | 5432 | 58 |
| Wanxin Biotechnology (Jiaxing) Co., LTD | 0573-83568680 18057391398 | 3956524501@qq.com | China | 1442 | 58 |
